ArticleInternational journal of nanomedicine2026
Electrospun PVP Nanofibrous Co-Loaded with Miconazole and Lidocaine for the Treatment of Oral Candidiasis.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral candidiasis caused by Rationale: To overcome these challenges, this study developed an electrospun nanofibrous patch for localized co-delivery of miconazole (MZ) and lidocaine (LD) to oral mucosa. MZ and LD were co-encapsulated in electrospun polyvinylpyrrolidone (PVP) nanofibers and evaluated for morphology, drug loading, release profile, minimum inhibitory concentration (MIC), cytotoxicity, and in vivo antifungal efficacy. Results: Scanning electron microscopy showed smooth fibers with an average diameter of 490 ± 122nm. Drug loading values were 41 µg/mg for LD and 46 µg/mg for MZ. Release studies demonstrated rapid LD release, with approximately 70% released within the first few minutes and complete release after 30 minutes. In contrast, MZ reached about 95% cumulative release within 120 minutes. The MZ/LD combination (1:1) showed potent antifungal activity, with an MIC of 0.004 μg/mL and an inhibition zone of 20 ± 1 mm. No in vitro cytotoxicity was observed at concentrations of < 16 µg/mL for MZ, < 1250 µg/mL for LD, and < 16 and 78 µg/mL for MZ and LD, respectively, for their combination. In a murine oral candidiasis model, MZ/LD-loaded nanofibers significantly (p< 0.0001) reduced fungal burden to 22 CFU/mL and improved tongue lesion scores compared with MZ-loaded nanofibers alone (1100 CFU/mL) and the commercial MZ formulation. Conclusion: These findings demonstrate that the developed dual-drug nanofibrous system is a safe and promising localized delivery system for treating oral candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.